Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
1.660
-0.060 (-3.49%)
At close: Nov 20, 2024, 4:00 PM
1.670
+0.010 (0.60%)
Pre-market: Nov 21, 2024, 7:14 AM EST
Gain Therapeutics Employees
As of December 31, 2023, Gain Therapeutics had 32 total employees, including 29 full-time and 3 part-time employees. The number of employees increased by 1 or 3.23% compared to the previous year.
Employees
32
Change (1Y)
1
Growth (1Y)
3.23%
Revenue / Employee
n/a
Profits / Employee
-$667,717
Market Cap
42.39M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 32 | 1 | 3.23% |
Dec 31, 2022 | 31 | 2 | 6.90% |
Dec 31, 2021 | 29 | 15 | 107.14% |
Dec 31, 2020 | 14 | 10 | 250.00% |
Dec 31, 2019 | 4 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Achilles Therapeutics | 215 |
Xilio Therapeutics | 73 |
Actinium Pharmaceuticals | 49 |
OncoCyte | 46 |
LAVA Therapeutics | 37 |
SCYNEXIS | 29 |
Serina Therapeutics | 11 |
Intensity Therapeutics | 7 |
GANX News
- 6 weeks ago - Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024 - GlobeNewsWire
- 7 weeks ago - Gain Therapeutics to Participate at Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson's Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers - GlobeNewsWire
- 2 months ago - Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease - GlobeNewsWire
- 2 months ago - Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson's Disease Models Including Two Late-Breakers at Neuroscience 2024 - GlobeNewsWire
- 3 months ago - Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease - GlobeNewsWire
- 3 months ago - Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson's Disease - GlobeNewsWire